Pfizer (PFE) reported fourth-quarter 2023 adjusted earnings per share of 10 cents in contrast to the Zacks Consensus Estimate of a loss of 19 cents per share. In the year-ago quarter, the company had recorded earnings of $1.41 per share.Revenues came in at $14.25 billion, down 41% from the year-ago quarter on a reported basis, reflecting an operational decline of 42% but a currency benefit of 1%. Total revenues missed the Zacks Consensus Estimate of $14.37 billion.The revenue decline, as expected, was due t ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Pfizer Inc (NYSE:PFE) entered the earnings ring before the bell this morning, announcing fourth-quarter earnings of 10 cents per share, which is higher than analysts' anticipated losses of 22 cents. Meanwhile, revenue of $14.25 billion came in lower than the expected $14.42 billion. In regard to 2024, the pharmaceutical giant reaffirmed its forecast. Pfizer stock has erased its earlier gains, currently down 1.7% at $27.02. The stock ran up to recent pressure at its 20-day moving average before the reversal, ...

Key TakeawaysPfizer reported a surprise profit in the fourth quarter despite double-digit revenue contraction.Adjusted income came in at $593 million or 10 cents per diluted share versus a loss expected by analysts.Fourth quarter revenue fell 41% from a year ago to $14.2 billion.Pfizer Inc. (PFE) delivered a surprise profit in the fourth quarter despite a double-digit contraction in revenue. Pfizer shares were up 1.8% in early trading Tuesday following the release.While analysts expected wider quarterly los ...

Pfizer (PFE) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 152.63%. A quarter ago, it was expected that this drugmaker would post a loss of $0.32 per share when it actually produced a loss of $0.17, delivering a surprise of 46.88%.Over the last four quarters, the company h ...

Shares of Pfizer Inc. PFE, +0.04% gained 0.7% early Tuesday after the company beat analysts’ earnings expectations and reaffirmed its full-year 2024 guidance issued in December. The drugmaker reported a fourth-quarter net loss of $3.37 billion, or 60 cents a share, compared with net income of $4.995 billion, or 87 cents a share, in the year-earlier period. Adjusted earnings per share came to 10 cents, beating the FactSet consensus of a loss of 18 cents per share. Revenues totaled $14.249 billion in the quar ...

Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021.Pfizer on Tuesday posted a surprise adjusted fourth-quarter profit, as the company slashed costs while demand for its Covid products plummeted.The company reversed roughly $3.5 billion in revenue related to the expected return of 6.5 ...

Pharmaceutical giant Pfizer on January 30th reported its financial results for Q4 and the full year of 2023.The company reported disappointing results, to say the least, including $58.5 billion in revenues for 2023 and $14.24 billion in revenues in Q4, down 42 percent and 41 percent from 2022 year-on-year. Paxlovid and Comirnaty Copy link to sectionA lot of this seemed to be due to acquisitions Paxlovid and Comirnaty, as the company said in its earnings announcement that:Expected Decline in Comirnaty and Pa ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and full-year 2023 and reaffirmed its 2024 financial guidance(5) provided on December 13, 2023. The fourth-quarter 2023 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfizer.com. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “ We are encouraged by the strong performance ...

Pfizer (PFE) has been relying on its newly launched and newly acquired products to improve its sales performance amid a decline in revenues from its COVID-19 products.Pfizer records direct sales and alliance revenues from its partner, BioNTech (BNTX) , for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill for COVID, Paxlovid.Investors will be keen to know the sales numbers of Pfizer’s several newly launched drugs like Abrysvo, Velsipity, Penbraya, Zavzpret as well as newly a ...